Loading…
Neurocrine Biosciences, Inc. is projected to rise to $231.64 by 2027, a +31% move from its current price of $177.11. NBIX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $174.38 | $177.14 | $179.94 | +0.02% |
| Jul 14 | $173.27 | $177.16 | $181.14 | +0.03% |
| Jul 15 | $172.44 | $177.19 | $182.08 | +0.05% |
| Jul 16 | $171.74 | $177.22 | $182.87 | +0.06% |
| Jul 17 | $171.13 | $177.25 | $183.58 | +0.08% |
| Jul 18 | $170.58 | $177.27 | $184.23 | +0.09% |
| Jul 19 | $170.08 | $177.30 | $184.82 | +0.11% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $170.08 | $177.30 | $184.82 | +0.11% |
| Week 2 | $167.36 | $177.49 | $188.24 | +0.22% |
| Week 3 | $165.34 | $177.68 | $190.94 | +0.32% |
| Week 4 | $163.69 | $177.87 | $193.29 | +0.43% |
| Week 5 | $162.26 | $178.06 | $195.41 | +0.54% |
| Week 6 | $161.00 | $178.26 | $197.36 | +0.65% |
| Week 7 | $159.87 | $178.45 | $199.19 | +0.76% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Neurocrine Biosciences, Inc. discovers, develops, and commercializes pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. Its products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offerings under the names ALKINDI and Efmody.
The company has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Neurocrine Biosciences, NBIX, is a pharmaceutical company focused on therapies for neurological, psychiatric, endocrine, and immunological disorders operating in the United States and internationally. The stock is currently priced at $170.00 per share and has a market capitalization of $16.94B. It is ranked 5261.
The near-term outlook is informed by a bullish longer-term forecast, with multi-year projections showing upside potential. The 2026 forecast carries an average price of $170.00, with a min of $123.10 and a max of $218.90, and a neutral sentiment; subsequent years turn increasingly bullish with rising averages and positive ROIs through 2050. These figures are projections and should be interpreted as estimates rather than guarantees.
A major floor 28.7% below — a decisive break under it would weaken the trend.
The nearest floor, 12.6% below — buyers have tended to step in here.
Price is pressing into resistance (1.9% away) — a breakout level to watch.
A major ceiling 11.0% above — clearing it would confirm fresh momentum.
Key NBIX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NBIX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $177.50 | Sell | $176.90 | Buy |
| MA 10 | $173.66 | Buy | $173.90 | Buy |
| MA 20 | $167.28 | Buy | $169.36 | Buy |
| MA 50 | $158.99 | Buy | $159.81 | Buy |
| MA 100 | $144.54 | Buy | $151.35 | Buy |
| MA 200 | $143.25 | Buy | $144.33 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 66.23 | Neutral |
| Stoch RSI (14) | 55.58 | Neutral |
| CCI (20) | 102.74 | Buy |
| Williams %R (14) | -18.00 | Info |
| MACD (12,26,9) | 0.88 | Buy |
| ROC (12) | 9.71 | Buy |
| Bollinger %B (20,2) | 0.83 | Neutral |
| Stochastic %K (14) | 82.00 | Sell |
| TRIX (15) | 0.42 | Buy |
| Awesome (5,34) | 13.22 | Buy |
| Ultimate (7,14,28) | 73.64 | Sell |
| Momentum (10) | 12.93 | Buy |
| Aroon Osc (25) | 60.00 | Buy |
| Hull MA (9) | 180.89 | Sell |
| ADX (14) | 29.12 | Buy |
| ATR (14) | 2.45 | Info |
The 30-day technical picture remains bullish, supported by RSI(14) at 70 and price momentum. The stock trades above the SMA50 of $151.83 and above the SMA200 of $142.00, signaling constructive medium-term momentum. The immediate support is $154.36, while resistance sits at $170.00.
The 30-day range spans from a low of $152.41 to a high of $189.61, reflecting a broad near-term trading band and ongoing volatility measured at 30% annualized. These technicals suggest room for upside in the near term, subject to broader market conditions and company-specific developments.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $123.10 | $177.11 | $224.25 | 0% | Neutral | |
| $189.72 | $231.64 | $295.69 | +31% | Bullish | |
| $224.83 | $279.67 | $366.67 | +58% | Bullish | |
| $279.69 | $353.27 | $473.03 | +99% | Bullish | |
| $319.82 | $409.42 | $558.09 | +131% | Bullish | |
| $342.36 | $443.63 | $614.28 | +150% | Bullish | |
| $385.29 | $504.90 | $709.06 | +185% | Bullish | |
| $415.75 | $550.56 | $783.18 | +211% | Bullish | |
| $496.50 | $664.04 | $955.91 | +275% | Bullish | |
| $603.60 | $814.91 | $1,186.16 | +360% | Bullish | |
| $889.81 | $1,252.98 | $1,911.24 | +607% | Bullish | |
| $1,692.85 | $2,556.58 | $4,180.21 | +13.4x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $123.10 | $177.11 | $207.47 | +0.00% |
| August 2026 | $149.70 | $175.22 | $209.52 | -1.07% |
| September 2026 | $152.71 | $179.61 | $216.46 | +2.51% |
| October 2026 | $152.82 | $180.48 | $218.94 | +0.48% |
| November 2026 | $150.68 | $178.57 | $217.82 | -1.06% |
| December 2026 | $153.84 | $182.91 | $224.25 | +2.43% |
Click any year to see its month-by-month NBIX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, NBIX is projected to trade between $123.10 and $224.25, averaging $177.11 — a potential gain of 0% from today's $177.11. Price action looks broadly range-bound.
Neurocrine Biosciences, Inc.'s 2027 outlook centres on $231.64, within a $189.72 to $295.69 range. That is up +31% on the projected 2026 average. That marks a +31% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, NBIX could reach as high as $366.67, with a base case around $279.67 and support toward $224.83 — roughly +58% from $177.11. Momentum favours further upside here.
Expect NBIX to range from $279.69 to $473.03 through 2029. The $353.27 average target implies a +99% move from current prices. That is up +26% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The NBIX price prediction for 2030 points to an average of $409.42 (low $319.82, high $558.09) — a potential gain of +131% on today's $177.11. Momentum favours further upside here.
In 2031, NBIX is projected to trade between $342.36 and $614.28, averaging $443.63 — a potential gain of +150% from today's $177.11. That is up +8% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Neurocrine Biosciences, Inc.'s 2032 outlook centres on $504.90, within a $385.29 to $709.06 range. That is up +14% on the projected 2031 average. That marks a +185% change versus current levels. Momentum favours further upside here.
By 2033, NBIX could reach as high as $783.18, with a base case around $550.56 and support toward $415.75 — roughly +211% from $177.11. Buyers look set to stay in control over this stretch.
Expect NBIX to range from $496.50 to $955.91 through 2034. The $664.04 average target implies a +275% move from current prices. That is up +21% on the projected 2033 average. Momentum favours further upside here.
The NBIX price prediction for 2035 points to an average of $814.91 (low $603.60, high $1,186.16) — a potential gain of +360% on today's $177.11. Buyers look set to stay in control over this stretch.
In 2040, NBIX is projected to trade between $889.81 and $1,911.24, averaging $1,252.98 — a potential gain of +607% from today's $177.11. That is up +54% on the projected 2035 average. Momentum favours further upside here.
Neurocrine Biosciences, Inc.'s 2050 outlook centres on $2,556.58, within a $1,692.85 to $4,180.21 range. That is up +104% on the projected 2040 average. That marks a +13.4x change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in NBIX today (≈ 5.646209 NBIX) could be worth
$14,435.01
+$13,435.01 (+1344%) by 2050 · US Dollar
Based on the average projected NBIX price of $2,556.58 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NBIXwould be worth at today's price.
$1,000 invested in NBIX on Jul 10, 2025 (≈ 7.4118 NBIX) would be worth
$1,312.7
+$312.7 (+31.3%) today · 1.31× · US Dollar
Based on a NBIX entry price of $134.92 vs. today's $177.11.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $174.26 | $1,016.35 | +1.6% |
| 1 month ago | $160.86 | $1,101.02 | +10.1% |
| 3 months ago | $128.89 | $1,374.12 | +37.4% |
| 6 months ago | $132.66 | $1,335.07 | +33.5% |
| 1 year ago | $134.92 | $1,312.7 | +31.3% |
| All time (5.0y) ago | $97.21 | $1,821.93 | +82.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NBIX forecast.
Our base-case forecast reaches $350.00 around 2029.
Implied market cap at $350.00: $35.19B
The multi-year forecast paints a strong bullish arc for NBIX. By 2030 the average price is projected to be $392.04 with a maximum of $534.68 and a minimum of $306.11, delivering an estimated ROI of 130.6% and a bullish sentiment. The path extends into 2040, where the average price is forecast at $1,187.66 with a max of $1,812.10 and a min of $843.21, for an ROI of 598.6% and continued bullishness.
By 2050 the average price is projected to reach $2,443.72 with a max of $3,996.45 and a min of $1,617.78, projecting an ROI of 1337.5% and a sustained bullish outlook.
Across the sequence from 2027 onward the forecast remains bullish, with 2027 averaging $222.56 and ROIs rising through 2028 (57.6%), 2029 (100.8%), 2030 (130.6%), and beyond, culminating in 2050 with a very large implied upside. These figures illustrate substantial long-term upside potential, though they are estimates and not guarantees, and actual results may vary with market and company-specific conditions.
Tap a question to reveal the answer.
Year 2030 forecast: avg $392.04, min $306.11, max $534.68, ROI 130.6%, sentiment BULLISH.
The forecast shows bullish sentiment from 2027 onward, with rising averages (e.g., 2027 avg $222.56; 2030 avg $392.04) and positive ROIs (up to 130.6% by 2030, and higher later), though these are estimates, not guarantees.
Yes. The forecast projects an average of $1,187.66 in 2040 and a max of $1,812.10 in that year, indicating potential to surpass $1,000 by 2040, with a very high late-range upside through 2050 (avg $2,443.72; max $3,996.45).
Current price is $170.00, with RSI(14) at 70. SMA50 is $151.83 and SMA200 is $142.00. Support is $154.36 and resistance is $170.00. The 30-day range is $152.41 to $189.61, and annualized volatility is 30%.
The forecast shows continued bullish momentum, with 2050 avg $2,443.72, min $1,617.78, max $3,996.45 and ROI 1337.5%. This reflects a long-run upside trajectory, subject to uncertainty and market conditions.
Neurocrine Biosciences, Inc. Community Discussion
0Share your Neurocrine Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.